In 2–15% of the cases, the mechanism of resistance to EGFR-TKI in NSCLC involves a histological transformation to small-cell lung cancer (SCLC) [22,42,43], highlighting the cancer cell’s plasticity and ability to phenotypically adapt to survive drug pressure. The gene discussed is EGFR; the disease is cancer.